Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 7, Issue 24

December 26 2023

In this Issue

EDITORIAL
ADVANCES VIEWPOINT
CLINICAL TRIALS AND OBSERVATIONS
HEALTH SERVICES AND OUTCOMES
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
RESEARCH LETTERS
COMMENTARIES

EDITORIAL

Celebrating a year of cancer research in Blood Advances

Catherine M. Bollard,Andrew Weyrich

View Articletitled, Celebrating a year of cancer research in Blood Advances

ADVANCES VIEWPOINT

New and emerging therapies for women, girls, and people with the potential to menstruate with VWD

Caterina Casari,Jennifer Leung,Paula D. James

View Articletitled, New and emerging therapies for women, girls, and people with the potential to menstruate with VWD

CLINICAL TRIALS AND OBSERVATIONS

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Clinical Trials & Observations

Raphael E. Steiner,Steven R. Hwang,Arushi Khurana,Thomas M. Habermann,Narendranath Epperla,Kaitlin Annunzio,Pamela Blair Allen,Katelin Baird,Darina Paulino,Juan Pablo Alderuccio,Izidore S. Lossos,Kevin David,Andrew M. Evens,Karan Pandya,Steven M. Bair,Manali Kamdar,Sheeba Ba Aqeel,Pallawi Torka,Ryan Lynch,Stephen Smith,Lei Feng,Mansoor Noorani,Sairah Ahmed,Ranjit Nair,Francisco Vega,Susan Wu,Penny Fang,Chelsea C. Pinnix,Jillian R. Gunther,Bouthaina S. Dabaja,Hun J. Lee

View Articletitled, Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma

Supplemental data

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Clinical Trials & Observations

Jessica K. Altman,Tsila Zuckerman,Jamie Koprivnikar,James McCloskey,Vamsi Kota,Michael Keng,Olga Frankfurt,Yasmin Abaza,Dale L. Bixby,Ashkan Emadi,Micah Burch,Bhavana Bhatnagar,Selina M. Luger,Mary-Elizabeth Percival,Ofir Wolach,Michael Craig,Chezi Ganzel,Gail Roboz,Itai Levi,Anna Gourevitch,Liat Flaishon,Shoshi Tessler,Chen Blumberg,Stela Gengrinovitch,Ruth Ben Yakar,Jacob M. Rowe

View Articletitled, Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
Clinical Trials & Observations

Saskia K. Klein,Gerwin A. Huls,Otto Visser,Hanneke C. Kluin-Nelemans,Avinash G. Dinmohamed

View Articletitled, Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study

Supplemental data

HEALTH SERVICES AND OUTCOMES

Telehealth serious illness care program for older adults with hematologic malignancies: a single-arm pilot study

Marissa LoCastro,Soroush Mortaz-Hedjri,Ying Wang,Jason H. Mendler,Sally Norton,Rachelle Bernacki,Thomas Carroll,Heidi Klepin,Jane Liesveld,Eric Huselton,Benzi Kluger,Kah Poh Loh

View Articletitled, Telehealth serious illness care program for older adults with hematologic malignancies: a single-arm pilot study

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content

Mehrnaz Safaee Talkhoncheh,Aurélie Baudet,Fredrik Ek,Agatheeswaran Subramaniam,Yun-Ruei Kao,Natsumi Miharada,Christine Karlsson,Leal Oburoglu,Anna Rydström,Kristijonas Zemaitis,Abdul Ghani Alattar,Justyna Rak,Kristian Pietras,Roger Olsson,Britta Will,Jonas Larsson

View Articletitled, Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content

Supplemental data

Gata2 noncoding genetic variation as a determinant of hematopoietic stem/progenitor cell mobilization efficiency

Alexandra A. Soukup,Emery H. Bresnick

View Articletitled, Gata2 noncoding genetic variation as a determinant of hematopoietic stem/progenitor cell mobilization efficiency

Supplemental data

LYMPHOID NEOPLASIA

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

James N. Gerson,Elizabeth Handorf,Diego Villa,Alina S. Gerrie,Parv Chapani,Shaoying Li,L. Jeffrey Medeiros,Michael Wang,Jonathon B. Cohen,Michael Churnetski,Brian T. Hill,Yazeed Sawalha,Francisco J. Hernandez-Ilizaliturri,Shalin Kothari,Julie M. Vose,Martin Bast,Timothy Fenske,Swapna Narayana Rao Gari,Kami J. Maddocks,David Bond,Veronika Bachanova,Bhaskar Kolla,Julio Chavez,Bijal Shah,Frederick Lansigan,Timothy Burns,Alexandra M. Donovan,Nina Wagner-Johnston,Marcus Messmer,Amitkumar Mehta,Jennifer K. Anderson,Nishitha Reddy,Alexandra E. Kovach,Daniel J. Landsburg,Martha Glenn,David J. Inwards,Kay Ristow,Reem Karmali,Jason B. Kaplan,Paolo F. Caimi,Saurabh Rajguru,Andrew Evens,Andreas Klein,Elvira Umyarova,Bhargavi Pulluri,Jennifer E. Amengual,Jennifer K. Lue,Catherine Diefenbach,Richard I. Fisher,Stefan K. Barta

View Articletitled, Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Supplemental data

Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma

Marie Beck Hairing Enemark,Katharina Wolter,Amanda Jessica Campbell,Maja Dam Andersen,Emma Frasez Sørensen,Trine Engelbrecht Hybel,Charlotte Madsen,Kristina Lystlund Lauridsen,Trine Lindhardt Plesner,Stephen Jacques Hamilton-Dutoit,Bent Honoré,Maja Ludvigsen

View Articletitled, Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma

Supplemental data

Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress

Beatriz Gomez Solsona,Heike Horn,Anja Schmitt,Wendan Xu,Philip Bucher,Aylin Heinrich,Sabrina Kalmbach,Nina Kreienkamp,Maik Franke,Florian Wimmers,Laurentz Schuhknecht,Andreas Rosenwald,Mattia Zampieri,German Ott,Georg Lenz,Klaus Schulze-Osthoff,Stephan Hailfinger

View Articletitled, Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress

Supplemental data

Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study

Tomohiro Urata,Yusuke Naoi,Aixiang Jiang,Merrill Boyle,Kazutaka Sunami,Toshi Imai,Yuichiro Nawa,Yasushi Hiramatsu,Kazuhiko Yamamoto,Soichiro Fujii,Isao Yoshida,Tomofumi Yano,Ryota Chijimatsu,Hiroyuki Murakami,Kazuhiro Ikeuchi,Hiroki Kobayashi,Katsuma Tani,Hideki Ujiie,Hirofumi Inoue,Shuta Tomida,Akira Yamamoto,Takumi Kondo,Hideaki Fujiwara,Noboru Asada,Hisakazu Nishimori,Keiko Fujii,Nobuharu Fujii,Ken-ichi Matsuoka,Keisuke Sawada,Shuji Momose,Jun-ichi Tamaru,Asami Nishikori,Yasuharu Sato,Tadashi Yoshino,Yoshinobu Maeda,David W. Scott,Daisuke Ennishi

View Articletitled, Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study

Supplemental data

MYELOID NEOPLASIA

Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome

Adriana Chiaramida,Sandra G. Obwar,Anja E. H. Nordstrom,Maria Ericsson,Aisha Saldanha,Elena V. Ivanova,Gabriel K. Griffin,Dilshad H. Khan,Roger Belizaire

View Articletitled, Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome

Supplemental data

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

Janghee Woo,Darlene Lu,Andrew Lewandowski,Huilei Xu,Pablo Serrano,Margaret Healey,Denise P. Yates,Michael T. Beste,Peter Libby,Paul M. Ridker,David P. Steensma

View Articletitled, Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

Supplemental data

JAK2^V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes

Maryam Rafati,Derek W. Brown,Weiyin Zhou,Kristine Jones,Wen Luo,Andrew St. Martin,Youjin Wang,Meilun He,Stephen R. Spellman,Tao Wang,H. Joachim Deeg,Vikas Gupta,Stephanie J. Lee,Yung-Tsi Bolon,Stephen J. Chanock,Mitchell J. Machiela,Wael Saber,Shahinaz M. Gadalla

View Articletitled, JAK2V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes

Supplemental data

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis

Yu Wei Zhang,Talia Velasco-Hernandez,Julian Mess,Maria-Eleni Lalioti,Mari Carmen Romero-Mulero,Nadine Obier,Nikolaos Karantzelis,Jasmin Rettkowski,Katharina Schönberger,Noémie Karabacz,Karin Jäcklein,Tatsuya Morishima,Juan Luis Trincado,Paola Romecin,Alba Martinez,Hitoshi Takizawa,Khalid Shoumariyeh,Simon Renders,Robert Zeiser,Heike L. Pahl,François Béliveau,Josée Hébert,Bernhard Lehnertz,Guy Sauvageau,Pablo Menendez,Nina Cabezas-Wallscheid

View Articletitled, GPRC5C drives branched-chain amino acid metabolism in leukemogenesis

Supplemental data

AMPK activation induces immunogenic cell death in AML

Johanna Mondesir,Margherita Ghisi,Laura Poillet,Robert A. Bossong,Oliver Kepp,Guido Kroemer,Jean-Emmanuel Sarry,Jérôme Tamburini,Andrew A. Lane

View Articletitled, AMPK activation induces immunogenic cell death in AML

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Effects of mitapivat-mediated pyruvate kinase activation in sickle cell disease. Mitapivat (AG-348) is an oral allosteric activator of pyruvate kinase (PK), a key enzyme in RBC glycolysis. PK activation decreases 2,3-DPG levels and increases ATP levels in RBCs. This study showed that mitapivat decreased parameters of hemolysis, RBC sickling and vaso-occlusive events and increased hemoglobin (Hb) level and Hb-oxygen affinity.1,3-DPG, 1,3-Disphosphoglycerate; ADP, adenosine diphosphate; P, phosphate; 2,3-DPG, 2,3-diphosphoglycerate; ATP, adenosine triphosphate; 3-PG, 3-Phosphoglycerate; PEP, phosphoenolpyruvate; RBC, red blood cell; Hb, hemoglobin.

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
Clinical Trials & Observations

Myrthe J. van Dijk,Minke A. E. Rab,Brigitte A. van Oirschot,Jennifer Bos,Cleo Derichs,Anita W. Rijneveld,Marjon H. Cnossen,Erfan Nur,Bart J. Biemond,Marije Bartels,Judith J. M. Jans,Wouter W. van Solinge,Roger E. G. Schutgens,Richard van Wijk,Eduard J. van Beers

View Articletitled, One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study

Supplemental data

THROMBOSIS AND HEMOSTASIS

Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation

Varun Iyengar,Rushad Patell,Siyang Ren,Sirui Ma,Amanda Pinson,Amelia Barnett,Pavania Elavalakanar,Dhruv S. Kazi,Donna Neuberg,Jeffrey I. Zwicker

View Articletitled, Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation

Supplemental data

TRANSFUSION MEDICINE

Eleven years of alloimmunization in 6496 patients with sickle cell disease in France who received transfusion

Aline Floch,Sophie Viret,Lucile Malard,Sadaf Pakdaman,Alicia Jouard,Anoosha Habibi,Frédéric Galacteros,Anne François,France Pirenne

View Articletitled, Eleven years of alloimmunization in 6496 patients with sickle cell disease in France who received transfusion

Supplemental data

RESEARCH LETTERS

TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data

Allen Gu,Breon Schmidt,Andrew Lonsdale,Roshan Jalaldeen,Hansen J. Kosasih,Lauren M. Brown,Teresa Sadras,Paul G. Ekert,Alicia Oshlack

View Articletitled, TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data

Supplemental data

Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia

Jerome Tamburini,Sarah Mouche,Clement Larrue,Nicolas Duployez,Audrey Bidet,Auriane Salotti,Pierre Hirsch,Lucie Rigolot,Sylvain Carras,Marie Templé,Fabrizia Favale,Pascale Flandrin-Gresta,Yannick Le Bris,Anne-Sophie Alary,Laurent Mauvieux,Sylvie Tondeur,Eric Delabesse,François Delhommeau,Pierre Sujobert,Olivier Kosmider,on behalf of the French GBMHM

View Articletitled, Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia

Supplemental data

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Clinical Trials & Observations

Yuan Jian,Long Chang,Ming-Xia Shi,Ying Sun,Xiao-Xia Chu,Hua Xue,Wen-Rong Huang,Xu-Liang Shen,Jie Ma,Guo-Rong Jia,Ya-Qing Feng,Zhen-Fang Xi,Yan-Hong Zhao,Yan-Ping Ma,Jing Xiao,Guang-Yu Ma,Qing-Ming Wang,Li Bao,Yu-Jun Dong,He-Bing Zhou,Chun-Yan Sun,Guo-Hong Su,Yan Yan,Sai-Yin Qimuge,Li-Ping Su,Jing-Nan Sun,Wei-Wei Tian,Xiu-Li Sun,Hong-Mei ing,Da Gao,Wen-Ming Chen,Jian Li,Wen Gao

View Articletitled, Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment

Supplemental data

COMMENTARIES

Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia
Clinical Trials & Observations

Richard M. Stone,Jessica K. Altman,Mikkael A. Sekeres

View Articletitled, Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia

Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?

Tiziano Barbui,Alessandra Carobbio,Alessandro M. Vannucchi,Valerio De Stefano

View Articletitled, Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?

Cover Image

Cover Image

Representative image of immunohistochemical staining of myeloid leukemia cell differentiation protein in diagnostic samples from follicular lymphoma. Magnification 20x. See the article by Enemark et al.
Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

How donor age affects RBC deformability in storage

Testicular follicular lymphoma: let me count the ways

Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Advertisement intended for health care professionals

Issue Archive

Table of Contents

EDITORIAL

ADVANCES VIEWPOINT

CLINICAL TRIALS AND OBSERVATIONS

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma Clinical Trials & Observations

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study Clinical Trials & Observations

Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study Clinical Trials & Observations

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study Clinical Trials & Observations

THROMBOSIS AND HEMOSTASIS

TRANSFUSION MEDICINE

RESEARCH LETTERS

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment Clinical Trials & Observations

COMMENTARIES

Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia Clinical Trials & Observations

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Clinical Trials & Observations

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Clinical Trials & Observations

Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
Clinical Trials & Observations

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
Clinical Trials & Observations

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Clinical Trials & Observations

Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia
Clinical Trials & Observations